Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
In development
Reference number: GID-TA11491
Expected publication date: TBC
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.